United Therapeutics (UTHR) Tops Q2 EPS by 82c
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $494.63 -0.53%
EPS Growth %: -10.1%
Financial Fact:
Operating income: 238.6M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -10.1%
Financial Fact:
Operating income: 238.6M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $3.68, $0.82 better than the analyst estimate of $2.86. Revenue for the quarter came in at $362 million versus the consensus estimate of $339.97 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Corpay agrees to $100M FTC settlement over marketing practices
- Amneal gets FDA approval for lanreotide injection, launches immediately
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
